GH · Guardant Health, Inc.

$157.58 -5.60 (-3.43%) At close · Aug 6

Market Cap

$21.15B

134.20M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Ines Dahne-Steuber	COO	$307,101	$50,000	$2,611,538	$2,550,722	—	$317,355	$5,836,716
Darya Chudova	CTO	$424,462	—	$2,222,397	$1,817,482	$279,281	$11,919	$4,755,541
Michael Bell	CFO	$482,000	—	$1,851,413	$1,453,305	$327,375	$9,900	$4,123,993
Christopher Freeman	Chief Commercial Officer	$490,385	—	$1,621,395	$1,075,387	$327,443	$8,442	$3,523,052
Craig Eagle	Chief Medical Officer	$497,462	—	$1,565,107	$1,075,387	$337,500	$9,900	$3,485,356
AmirAli Talasaz	CEO	$1	—	—	—	—	$26,414	$26,415
Helmy Eltoukhy	CEO	$1	—	—	—	—	$11,590	$11,591

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Christopher Freeman	Chief Commercial Officer	$468,269	—	$1,456,309	$1,882,865	$152,760	$9,364	$3,969,567
Craig Eagle	Chief Medical Officer	$485,231	—	$1,294,507	$1,673,671	$157,262	$6,642	$3,617,313
Michael Bell	CFO	$466,077	—	$604,238	$742,480	$154,958	$9,959	$1,977,712
Helmy Eltoukhy	CEO	$1	—	—	—	—	$11,631	$11,632
AmirAli Talasaz	CEO	$1	—	—	—	—	$11,174	$11,175

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Bell	CFO	$439,616	$500,000	$2,941,720	$2,317,493	$250,155	$10,998	$6,459,981
Craig Eagle	Chief Medical Officer	$317,885	$2,370,000	$1,642,986	$1,935,250	$186,390	$3,531	$6,456,043
Christopher Freeman	Chief Commercial Officer	$249,231	$300,000	$2,156,323	$2,539,902	$183,938	$7,056	$5,436,449
John Saia	Chief Legal Officer and Corporate Secretary	$413,654	$30,000	$495,020	$577,753	$187,454	$10,112	$1,713,993
Helmy Eltoukhy	CEO	$1	—	—	—	—	$13,664	$13,665
AmirAli Talasaz	CEO	$1	—	—	—	—	$13,270	$13,271

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
AmirAli Talasaz	CEO	$209,937	—	$113,595,323	—	—	$79,780	$113,885,040
Helmy Eltoukhy	CEO	$209,937	—	$113,595,323	—	—	$65,726	$113,870,986
Corporate Secretary	—	$304,346	$30,000	$1,362,000	$1,234,607	$196,800	$9,359	$3,137,112
John Saia	General Counsel	$304,346	$30,000	$1,362,000	$1,234,607	$196,800	$9,359	$3,137,112
Michael Wiley	Head of Corporate Affairs	$395,000	—	$1,112,792	—	$227,520	$17,856	$1,753,168
Derek Bertocci	CFO	$376,390	—	—	—	—	$13,510	$389,900

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Richard Lanman	Former Chief Medical Officer	$433,000	$100,000	$906,534	$1,619,262	—	$7,146	$3,065,942
Michael Wiley	Head of Corporate Affairs	$392,250	—	$543,958	$971,591	$306,323	$1,945	$2,216,067
Derek Bertocci	CFO	$378,313	—	$543,958	$971,591	$226,512	$9,234	$2,129,608
AmirAli Talasaz	CEO	$500,000	—	—	—	$412,500	$2,406	$914,906
Helmy Eltoukhy	CEO	$500,000	—	—	—	$412,500	$2,406	$914,906

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Richard Lanman	Former Chief Medical Officer	$367,666	$86,824	—	$338,000	$64,176	$5,926	$862,592
AmirAli Talasaz	President & Co-Founder	$480,000	—	—	—	$336,000	$2,405	$818,405
Helmy Eltoukhy	CEO	$480,000	—	—	—	$336,000	$2,405	$818,405
Michael Wiley	Head of Corporate Affairs	$384,000	—	—	—	$269,000	$1,461	$654,461

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Helmy Eltoukhy	CEO	$460,000	—	—	$3,459,658	$215,050	$1,405	$4,136,113
AmirAli Talasaz	President & Co-Founder	$460,000	—	—	$3,459,658	$215,050	$1,405	$4,136,113
Michael Wiley	Head of Corporate Affairs	$384,000	—	—	$470,746	$179,520	$1,461	$1,035,727

Executive changes

Person	Role	Change	Effective	Filed
Craig Eagle, M.D.	Chief Medical Officer	Resigned	2026-05-08	2026-04-27
Alex M. Azar II	Class III director	Appointed	2025-09-12	2025-09-15
Roberto Mignone	Class I director	Appointed	2024-10-21	2024-10-24
Manuel Hidalgo Medina, M.D., Ph.D.	Class II director	Appointed	2024-07-17	2024-07-18
Samir Kaul	member of the Board	Resigned	2024-02-01	2024-02-01

Key facts CIK 1576280 CUSIP 40131M109 13F (30d) 219 filings 194 filers Visit website Investor relations